# US 2026/0061024 A1 · Nasal delivery of apigenin and linear peptide inhibitors of mitochondrial fission

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061024 A1
- Document ID: US20260061024A1
- Status: Published application
- Kind: A1
- Application number: 18/911,604
- Filed: 2024-10-10
- Published: 2026-03-05
- Earliest claimed: 2024-08-30
- Assignees: NeuroTher, LLC
- Applicants: NeuroTher, LLC
- Inventors: Bhanu Pratap Jena; Guillermo G. Marmol; Won Jin Cho
- Web page: https://patentgrep.com/patent/US20260061024A1

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 9/0043: {Nose}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are multi-peptide compositions and/or methods of use of the multi-peptide compositions for subjects suffering from or at risk for a neural disease. Pharmaceutically acceptable embodiments administered subjects may treat or prevent the neural disease. In certain embodiments, a flavonoid compound is administered in conjunction with a peptide. In still other embodiments, a porosome complex is administered with the peptide and/or with the flavonoid compound.

## Claims

### Claim 1

A composition comprising:
a flavonoid; and,
at least one linear peptide associated with mitochondrial fission;
wherein the composition is pharmaceutically acceptable for administration to a subject.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the at least one linear peptide has a sequence corresponding to SEQ. ID. NO: 1.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the at least one linear peptide has a sequence of at least 70% identity to SEQ. ID. NO: 1.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the composition is a nanoemulsion for nasal administration.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the at least one linear peptide encodes a Drp1 adaptor protein or part thereof.

### Claim 6 (depends on 1)

The composition of claim 1 further comprising at least one additional peptide.

### Claim 7 (depends on 1)

The composition of claim 1 wherein the flavonoid is apigenin.

### Claim 8 (depends on 1)

The composition of claim 1 further comprising a porosome complex.

### Claim 9

A composition, comprising:
apigenin; and,
at least one DA1 based linear peptide.

### Claim 10 (depends on 9)

The composition of claim 9 further comprising a porosome complex.

### Claim 11 (depends on 9)

The composition of claim 9 wherein the composition further comprises at least one additional pharmaceutical excipient.

### Claim 12 (depends on 11)

The composition of claim 11 wherein the composition is prepared in the form of a nanoemulsion.

### Claim 13 (depends on 11)

The composition of claim 11 wherein the composition is prepared in the form of a suspended mist, powder, or solution.

### Claim 14 (depends on 1)

A method, comprising:
administering to a subject the composition of claim 1.